Long‐term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study

Malignant bone disease can cause significant morbidity. Monthly zoledronic acid (ZOL) reduces skeletal complications; however, limited data are available regarding long‐term safety. We aimed to assess efficacy and safety of ZOL beyond 1 year of treatment. We prospectively evaluated 73 patients; brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalafallah, A.A., Slancar, M., Cosolo, W., Abdi, E., Chern, B., Woodfield, R.J., Copeman, M.C., Briscoe, K., Catley, L., Chirgwin, J., Craft, P., Frydenberg, M., Hamilton, K., Hill, J., Irving, I., Lowenthal, R., Sullivan, A., Thompson, J., Watson, A‐M., Woodward, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901400/
https://www.ncbi.nlm.nih.gov/pubmed/28134499
http://dx.doi.org/10.1111/ecc.12638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901400/
https://www.ncbi.nlm.nih.gov/pubmed/28134499
http://dx.doi.org/10.1111/ecc.12638

Ejemplares similares